Messenger RNA (mRNA) News and Research

RSS

Nanopore sequencing contradicts human genome integration of SARS-CoV-2

Now a new preprint research paper posted to the bioRxiv* server dismisses the possibility, raised by that study, that the virus inserts its genetic material into the host cell’s genome.

2 Jun 2021

E484K mutation may confer immune evasion capability on UK variant of SARS-CoV-2

A new medRxiv* preprint reports the immunomodulatory effect of the E484K mutation newly acquired by the United Kingdom (U.K.) variant.

2 Jun 2021

An exploratory study of T-cell and antibody responses after COVID-19 mRNA vaccination

Recent COVID-19 investigations have found that up to half of immunocompromised individuals struggle to produce antibodies after receiving their severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations.

26 May 2021

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

The aim of this study investigates the impact of different types of vaccines on the anti-SARS-CoV-2 Immunoglobulin A (IgA) and Immunoglobulin G (IgG) antibody levels found in human milk.

25 May 2021

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Among the devastating complications of severe or critical coronavirus disease 2019 (COVID-19), clot formation ranks high in the adverse impact it creates. An important question is whether SARS-CoV-2-spike-based vaccines also cause such coagulopathies. A new study, released as a preprint on the medRxiv* server, examines this risk for the first time.

21 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Nanopore analysis identifies pseudouridine modifications in SARS-CoV-2

In a paper recently uploaded to the preprint server bioRxiv* by Fleming, Mathewson & Burrows (May 10th, 2021), nanopore devices are developed that allow identification of the passage of pseudouridine through a protein sensor. This further allowed the group to identify five conserved pseudouridine sites on the 3’ end of SARS-CoV-2 sub-genomic RNAs, which could potentially be beneficial to the virus in immune evasion.

17 May 2021

Three-way strategy employed by SARS-CoV-2 during infection

The study, published in the journal Nature, reveals a multi-pronged strategy that the virus employs to ensure its quick and efficient replication while evading the immune system. The study elucidated how the virus can quickly, in a matter of hours, take over the cell's protein-making machinery and parallelly neutralize the cell's antiviral signaling, thus delaying and muddling the immune response.

13 May 2021

No placental damage observed in case study of pregnant women with mRNA COVID-19 vaccinations

New research by a team at Northwestern University Feinberg School of Medicine, USA, suggests that the COVID-19 vaccine does not damage the placenta and may be safe to use during pregnancy.

13 May 2021

mRNA-based COVID-19 vaccines are effective against Indian SARS-CoV-2 variant, says study

A team of scientists recently conducted a study to examine whether natural infection-induced or vaccine-induced neutralizing antibodies are capable of eliminating the risk of recently emerged Indian variant (B.1.617.1) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

12 May 2021

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers in The Netherlands have warned that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces complex reprogramming of innate immune responses that should be considered in the development and use of mRNA-based vaccines.

10 May 2021

Study: Second vaccine dose still makes organ transplant recipients vulnerable to COVID-19

In a study published today in the Journal of the American Medical Association (JAMA), Johns Hopkins Medicine researchers show that although two doses of a vaccine against SARS-CoV-2 - the virus that causes COVID 19 - confers some protection for people who have received solid organ transplants, it's still not enough to enable them to dispense with masks, physical distancing and other safety measures.

6 May 2021

Pfizer/BioNTech and Moderna vaccines induce T-cell immunity against SARS-CoV-2

Researchers in the United States have shown that the Pfizer/BioNTech and Moderna messenger RNA (mRNA) vaccines are effective at generating T-cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 May 2021

Proteomic and transcriptomic profiling provide a full picture of aging process in the kidneys

Studying protein changes in the kidneys as we age, as well as the transcription of genes into proteins, helps provide a full picture of the age-related processes that take place in these organs, says a study in mice published today in eLife.

4 May 2021

Moderna COVID-19 vaccine makes it on WHO Emergency Use Listing

Moderna has announced Emergency Use Listing granted by the World Health Organization for its COVID-19 mRNA vaccine.

4 May 2021

Researchers discover new way to improve the subcutaneous administration of mRNA

If not before, then certainly since the first messenger RNA (mRNA) vaccines to combat the SARS CoV2 virus were approved in Germany, mRNA has become a recognized term even outside scientific circles.

4 May 2021

Could CRISPR be used as a SARS-CoV-2 antiviral?

The potential of using this gene manipulation technology as a SARS-CoV-2 inhibitor or prophylactic is investigated in a review recently uploaded to the journal Experimental Biology and Medicine (April 25th, 2021) by Arnab Banerjee and colleagues.

2 May 2021

Study of 180 breastfeeding mothers after mRNA COVID-19 vaccination

Vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, were developed at an unprecedented pace. To date, more than 1 billion vaccine doses have been administered worldwide, many of which messenger RNA (mRNA) based.

29 Apr 2021

Study examines mRNA COVID-19 vaccine’s effectiveness across age and gender

The findings reveal that although the two-dose vaccine regimen initially induces robust antibody response in all age groups, older male individuals are particularly associated with a gradual decline in vaccine-induced immunity six weeks after the second vaccine dose.

28 Apr 2021

Previous SARS-CoV-2 infection associated with more adverse events following mRNA vaccination

The phase 3 trials of the Pfizer and Moderna COVID-19 vaccines did not include those with a known previous SARS-CoV-2 infection. Recent evidence indicates that mRNA vaccines may induce more adverse events in these individuals. In a recent study, 947 individuals, 265 of which have previously reported SARS-CoV-2 infection, were monitored post-vaccination for adverse events, finding that there could be a link between previous infection and greater incidence of these events.

26 Apr 2021

Messenger RNA (mRNA) News and Research

Nanopore sequencing contradicts human genome integration of SARS-CoV-2

E484K mutation may confer immune evasion capability on UK variant of SARS-CoV-2

An exploratory study of T-cell and antibody responses after COVID-19 mRNA vaccination

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Nanopore analysis identifies pseudouridine modifications in SARS-CoV-2

Three-way strategy employed by SARS-CoV-2 during infection

No placental damage observed in case study of pregnant women with mRNA COVID-19 vaccinations

mRNA-based COVID-19 vaccines are effective against Indian SARS-CoV-2 variant, says study

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Study: Second vaccine dose still makes organ transplant recipients vulnerable to COVID-19

Pfizer/BioNTech and Moderna vaccines induce T-cell immunity against SARS-CoV-2

Proteomic and transcriptomic profiling provide a full picture of aging process in the kidneys

Moderna COVID-19 vaccine makes it on WHO Emergency Use Listing

Researchers discover new way to improve the subcutaneous administration of mRNA

Could CRISPR be used as a SARS-CoV-2 antiviral?

Study of 180 breastfeeding mothers after mRNA COVID-19 vaccination

Study examines mRNA COVID-19 vaccine’s effectiveness across age and gender

Previous SARS-CoV-2 infection associated with more adverse events following mRNA vaccination

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring